
A retrospective study of 144 eyes treated with Brolucizumab for resistant nAMD and PCV found intraocular inflammation in 4.9% of cases. Proactive monitoring and early steroid intervention ensured favorable visual outcomes, underscoring the safety of Brolucizumab when carefully managed.
Like
Save
Share